These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1217 related items for PubMed ID: 20357160

  • 21. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
    de Boer HD, van Esmond J, Booij LH, Driessen JJ.
    Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
    [Abstract] [Full Text] [Related]

  • 22. An update on sugammadex sodium.
    Welliver M, Cheek D.
    AANA J; 2009 Jun; 77(3):219-28. PubMed ID: 19645172
    [Abstract] [Full Text] [Related]

  • 23. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
    Herring WJ, Woo T, Assaid CA, Lupinacci RJ, Lemmens HJ, Blobner M, Khuenl-Brady KS.
    J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
    [Abstract] [Full Text] [Related]

  • 24. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study.
    Della Rocca G, Pompei L, Pagan DE Paganis C, Tesoro S, Mendola C, Boninsegni P, Tempia A, Manstretta S, Zamidei L, Gratarola A, Murabito P, Fuggiano L, DI Marco P.
    Acta Anaesthesiol Scand; 2013 Oct; 57(9):1138-45. PubMed ID: 23849107
    [Abstract] [Full Text] [Related]

  • 25. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M, Nakatsuka I, Takeda J.
    Anesth Analg; 2013 Aug; 117(2):345-51. PubMed ID: 23757472
    [Abstract] [Full Text] [Related]

  • 26. Preclinical pharmacology of sugammadex.
    Bom A, Hope F, Rutherford S, Thomson K.
    J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
    [Abstract] [Full Text] [Related]

  • 27. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.
    Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M.
    Anesthesiology; 2009 May; 110(5):1020-5. PubMed ID: 19387176
    [Abstract] [Full Text] [Related]

  • 28. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
    Lee C, Katz RL.
    J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
    [Abstract] [Full Text] [Related]

  • 29. Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.
    Hogg RM, Mirakhur RK.
    Expert Rev Neurother; 2009 May; 9(5):599-608. PubMed ID: 19402771
    [Abstract] [Full Text] [Related]

  • 30. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane.
    Vanacker BF, Vermeyen KM, Struys MM, Rietbergen H, Vandermeersch E, Saldien V, Kalmar AF, Prins ME.
    Anesth Analg; 2007 Mar; 104(3):563-8. PubMed ID: 17312209
    [Abstract] [Full Text] [Related]

  • 31. Sugammadex: A Review of Neuromuscular Blockade Reversal.
    Keating GM.
    Drugs; 2016 Jul; 76(10):1041-52. PubMed ID: 27324403
    [Abstract] [Full Text] [Related]

  • 32. Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Nicholson WT, Sprung J, Jankowski CJ.
    Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516
    [Abstract] [Full Text] [Related]

  • 33. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
    Rex C, Wagner S, Spies C, Scholz J, Rietbergen H, Heeringa M, Wulf H.
    Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873
    [Abstract] [Full Text] [Related]

  • 34. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    Brueckmann B, Sasaki N, Grobara P, Li MK, Woo T, de Bie J, Maktabi M, Lee J, Kwo J, Pino R, Sabouri AS, McGovern F, Staehr-Rye AK, Eikermann M.
    Br J Anaesth; 2015 Nov; 115(5):743-51. PubMed ID: 25935840
    [Abstract] [Full Text] [Related]

  • 35. The use of sugammadex in a patient with myasthenia gravis.
    Unterbuchner C, Fink H, Blobner M.
    Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
    [Abstract] [Full Text] [Related]

  • 36. Sugammadex: the first selective binding reversal agent for neuromuscular block.
    Kovac AL.
    J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium: a randomized controlled trial.
    Czarnetzki C, Tassonyi E, Lysakowski C, Elia N, Tramèr MR.
    Anesthesiology; 2014 Jul; 121(1):59-67. PubMed ID: 24608361
    [Abstract] [Full Text] [Related]

  • 38. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
    Mosing M, Auer U, West E, Jones RS, Hunter JM.
    Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
    [Abstract] [Full Text] [Related]

  • 39. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
    Rex C, Bergner UA, Pühringer FK.
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
    [Abstract] [Full Text] [Related]

  • 40. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation.
    Pongrácz A, Szatmári S, Nemes R, Fülesdi B, Tassonyi E.
    Anesthesiology; 2013 Jul; 119(1):36-42. PubMed ID: 23665915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 61.